Recombinant Cynomolgus DcR3/TNFRSF6B Fc Chimera Protein, CF

Recombinant Cynomolgus Monkey DcR3/TNFRSF6B Fc Chimera (Catalog #9297-DC) inhibits Recombinant Human Fas Ligand/TNFSF6 (Catalog # 126-FL) induced apoptosis of Jurkat human acute T cell leukemia cells. The ED50 for this effect is15-75 ng/mL.

• Reactivity: Pm-Cm
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus DcR3/TNFRSF6B Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit Fas Ligand-induced apoptosis of Jurkat human acute T cell leukemia cells. Cheng, J. et al. (1994) Science 263:1759. The ED₅₀ for this effect is 15‑75 ng/mL in the presence of 20 ng/mL Recombinant Human Fas Ligand/TNFSF6 (Catalog # 126-FL).
• Source: Chinese Hamster Ovary cell line, CHO-derived cynomolgus monkey DcR3/TNFRSF6B protein
  

  Cynomolgus Monkey DcR3/TNFRSF6B (Ala30-His300) Accession # EHH65162	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: EHH65162
• N-terminal Sequence: Ala30
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 56 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 58-67 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in MES and NaCl.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus DcR3/TNFRSF6B Fc Chimera Protein, CF

• DcR3
• DCR3Decoy receptor for Fas ligand
• Decoy receptor 3
• M68
• M68DJ583P15.1.1
• TNFRSF6B
• TR6
• TR6DcR3
• tumor necrosis factor receptor superfamily member 6B
• tumor necrosis factor receptor superfamily, member 6b, decoy

Background

DcR3 (Decoy Receptor 3), also known as TR6 and TNFRSF6B is a 35-40 kDa secreted member of the TNF Receptor superfamily (1). Mature cynomolgus DcR3 contains four tandem TNFR cysteine-rich domains and shares 92% amino acid sequence identity with human DcR3. It binds to the TNF superfamily ligands Fas Ligand, TL1A, and LIGHT (2-5) and interferes with their respective interactions with Fas, DR3, or HVEM and Lymphotoxin beta R (2-4). It blocks apoptosis triggered through either Fas Ligand, TL1A, or LIGHT (2, 3, 5, 6). DcR3 is up-regulated in a variety of cancers and enhances tumor cell immune evasion (2, 3, 7). It also promotes immune suppression by inducing dendritic cell apoptosis (8), inhibiting NK cell and CD8⁺ T cell activity (2, 4), and inhibiting the production of inflammatory cytokines during viral infection or autoimmunity (9, 10). In humans, proteolytic removal of the C-terminal 53 amino acids generates a shortened DcR3 that retains the ability to block LIGHT but not Fas Ligand induced apoptosis (11). DcR3 can also induce osteoclast formation from monocytes (12).

1. Siakavellas, S.I. and G. Bamias (2015) Inflamm. Bowel Dis. 21:2441.
2. Pitti, R.M. et al. (1998) Nature 396:699.
3. Yu, K.Y. et al. (1999) J. Biol. Chem. 274:13733.
4. Zhang, J. et al. (2001) J. Clin. Invest. 107:1459.
5. Migone, T.S. et al. (2002) Immunity 16:479.
6. Han, B. and J. Wu (2009) J. Immunol. 183:8157.
7. Ge, Z. et al. (2011) Exp. Ther. Med. 2:167.
8. You, R.I. et al. (2008) Blood 111:1480.
9. Huang, M.T. et al. (2015) J. Mol. Med. (Berlin) 93:1131.
10. Mueller, A.M. et al. (2009) J. Neuroimmunol. 209:57.
11. Wroblewski, V.J. et al. (2003) Biochem. Pharmacol. 65:657.
12. Yang, C.R. et al. (2004) Cell Death Differ. 11 Suppl 1:S97.

Bioinformatics

• Uniprot:
  • EHH65162()